7.4 Neurologic, Breast, and Neuroendocrine PET Agents
Key Takeaways
- F-18 fluorodopa is an amino-acid analog decarboxylated and stored in presynaptic vesicles; the labeled adult dose is about 5 mCi (185 MBq) with imaging roughly 75–90 minutes after injection to visualize striatal dopaminergic terminals in suspected Parkinsonian syndromes.
- F-18 fluoroestradiol (Cerianna®) images estrogen-receptor-positive breast lesions; ER-blocking drugs must be discontinued for at least five biological half-lives (tamoxifen up to 8 weeks, fulvestrant up to 28 weeks) or the study reads falsely negative.
- Amyloid agents (florbetapir, florbetaben, flutemetamol) bind beta-amyloid plaque, while F-18 flortaucipir binds paired-helical-filament tau—different targets, different uptake windows, and neither one alone diagnoses Alzheimer disease.
- Somatostatin-receptor PET uses Ga-68 dotatate/dotatoc (Ga-68 half-life about 68 minutes, generator-produced) or Cu-64 dotatate (half-life about 12.7 hours), which ships like a unit dose instead of requiring an on-site generator.
- Ga-68 gozetotide is the nonproprietary name for the Ga-68 PSMA-11 products marketed as Illuccix® and Locametz®; F-18 piflufolastat (Pylarify®) is the F-18 PSMA alternative with easier distribution logistics.
7.4 Neurologic, Breast, and Neuroendocrine PET Agents
Quick Answer: Fluorodopa → striatal dopaminergic terminals (≈5 mCi, image 75–90 min). Fluoroestradiol (Cerianna®) → ER-positive breast lesions (hold SERMs/SERDs for 5 biological half-lives). Amyloid trio → plaque; flortaucipir → tau. Ga-68/Cu-64 dotatate → somatostatin receptors. Ga-68 gozetotide (PSMA-11) and F-18 piflufolastat → PSMA. The failure mode is almost never the camera—it is an unheld drug or a wrong uptake clock.
Section 7.3 covered the PET workhorses (FDG, NaF, cardiac perfusion) and named the broader catalog. The COPS 2024 blueprint lists every one of these agents individually, so each deserves its own mechanism, prep rule, and trap.
F-18 Fluorodopa (FDOPA)
Mechanism. Fluorodopa is a fluorinated analog of L-DOPA. It crosses the blood–brain barrier on the large neutral amino acid transporter, is decarboxylated by aromatic amino acid decarboxylase (AADC) to F-18 fluorodopamine, and is stored in presynaptic vesicles. Signal therefore reflects the integrity of presynaptic dopaminergic terminals—the same biology DaTscan interrogates from the transporter side.
| Item | Practice |
|---|---|
| Approved use | PET visualization of dopaminergic nerve terminals in the striatum in adults with suspected Parkinsonian syndromes |
| Adult activity | About 5 mCi (185 MBq) IV, infused over roughly one minute |
| Imaging window | Optimal about 75–90 minutes after injection per labeling |
| Premedication | Carbidopa pretreatment is used in some protocols (especially non-neurologic indications) to block peripheral decarboxylation and raise brain uptake—follow the site protocol |
| Other uses | Neuroendocrine tumors, congenital hyperinsulinism, and selected brain tumors at specialized centers |
Traps: confusing FDOPA (a PET, presynaptic synthesis/storage tracer) with I-123 ioflupane (a SPECT, transporter-binding tracer); imaging too early; failing to control head motion during a long striatal acquisition.
F-18 Fluoroestradiol (Cerianna®)
Mechanism. An estradiol analog that binds the estrogen receptor (ER). It is used as an adjunct to biopsy to detect ER-positive lesions in recurrent or metastatic breast cancer.
| Item | Practice |
|---|---|
| Imaging start | Recommended about 80 minutes after IV administration |
| Critical hold | Discontinue ER-blocking drugs for at least five biological half-lives. Tamoxifen can occupy the receptor for up to 8 weeks; fulvestrant for up to 28 weeks |
| Physiologic uptake | Liver (dominant, hepatic metabolism), intestine, kidneys, bladder |
| Trap | A patient still on a SERM or SERD produces a falsely negative study; screening the medication list is the technologist's job |
Intense hepatic activity means liver metastases are the weak spot for this agent—know that limitation.
Amyloid Versus Tau
| Agent | Target | Notes |
|---|---|---|
| F-18 florbetapir (Amyvid®) | Beta-amyloid plaque | Short uptake window; grayscale or color display per training |
| F-18 florbetaben (Neuraceq®) | Beta-amyloid plaque | Uptake window typically starts later than florbetapir |
| F-18 flutemetamol (Vizamyl®) | Beta-amyloid plaque | Color-scale reading is part of the approved training |
| F-18 flortaucipir (Tauvid®) | Paired-helical-filament tau | Different protein, different distribution (medial temporal to neocortical progression) |
All four require motion-free brain PET with the head immobilized and a reconstruction that preserves gray–white contrast. Amyloid and tau agents are read by trained interpreters against approved criteria; quantitative scales such as Centiloid support but do not replace visual reading. Amyloid-positive is not a diagnosis of Alzheimer disease.
Somatostatin-Receptor PET
| Agent | Nuclide half-life | Logistics |
|---|---|---|
| Ga-68 dotatate (Netspot®) | Ga-68 ≈ 68 min | Ge-68/Ga-68 generator on site or regional same-day delivery; kit reconstitution and elution QC |
| Ga-68 dotatoc | Ga-68 ≈ 68 min | Same generator chemistry; availability varies by site |
| Cu-64 dotatate (Detectnet®) | Cu-64 ≈ 12.7 h | Ships as a unit dose; no generator, wider delivery radius |
Prep note: long-acting cold somatostatin analogs (octreotide LAR, lanreotide) compete for the same receptors; scheduling relative to the last therapy injection follows the protocol. These agents are also the diagnostic gate for Lu-177 dotatate therapy—receptor-positive imaging precedes peptide receptor radionuclide therapy.
PSMA-Targeted PET
| Agent | Nuclide | Naming note |
|---|---|---|
| Ga-68 gozetotide (Illuccix®, Locametz®) | Ga-68 | Gozetotide is the nonproprietary name for the PSMA-11 ligand—expect either term on an exam item |
| F-18 piflufolastat (Pylarify®) | F-18 (110 min) | Longer half-life eases distribution to sites without a generator |
Physiologic PSMA uptake in lacrimal and salivary glands, liver, spleen, small bowel, kidneys, and bladder is normal—do not treat it as disease. PSMA imaging also selects patients for Lu-177 PSMA therapy, tying §7.4 directly to §8.1.
Selection Table
| Clinical question | Agent |
|---|---|
| Suspected Parkinsonian syndrome, PET available | F-18 fluorodopa |
| Is this recurrent breast lesion ER-positive? | F-18 fluoroestradiol |
| Amyloid status in cognitive impairment | Florbetapir / florbetaben / flutemetamol |
| Tau burden and distribution | F-18 flortaucipir |
| Neuroendocrine tumor staging or PRRT selection | Ga-68 or Cu-64 dotatate/dotatoc |
| Prostate cancer staging or recurrence | Ga-68 gozetotide or F-18 piflufolastat |
Bottom line: each specialty PET agent has one biological target and one prep rule that can invalidate it. Learn the pair, and the item writes itself.
A patient is scheduled for F-18 fluoroestradiol (Cerianna®) PET to assess estrogen-receptor status of a recurrent breast lesion. Which screening finding most requires escalation before the study proceeds?
Which statement correctly contrasts F-18 fluorodopa with I-123 ioflupane (DaTscan®)?
Ga-68 gozetotide is best described as which of the following?